-Reuters
Takeda Reports TAKHZYRO Approved In Japan For Prophylaxis Against Acute attacks Of Hereditary Angioedema
− TAKHZYRO Approved for Adult and Pediatric Patients 12 Years of Age and Older1
− Approval Based on Results of Global Phase 3 HELP Study™, Phase 3 HELP OLE and a Phase 3 Study in Japanese Patients